Novel Mitochondria-targeted Drugs for Cancer Therapy

J 2021

Novel Mitochondria-targeted Drugs for Cancer Therapy

LEISCHNER FIALOVÁ, Jindřiška, Martina RAUDENSKÁ, Milan JAKUBEK, Zdenek KEJIK, Pavel MARTÁSEK et. al.

Basic information

Original name

Novel Mitochondria-targeted Drugs for Cancer Therapy

Authors

LEISCHNER FIALOVÁ, Jindřiška (203 Czech Republic, guarantor, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Milan JAKUBEK (203 Czech Republic), Zdenek KEJIK (203 Czech Republic), Pavel MARTÁSEK (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Adam MATKOWSKI (616 Poland), Petr FILIPENSKY (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, belonging to the institution)

Edition

Mini-reviews in medicinal chemistry, SHARJAH, BENTHAM SCIENCE PUBL LTD, 2021, 1389-5575

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30107 Medicinal chemistry

Country of publisher

United Arab Emirates

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.737

RIV identification code

RIV/00216224:14110/21:00118840

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2174/1389557520666201118153242

UT WoS

000631285400003

Keywords in English

Mitochondria; targeting; metabolism; cancer; treatment; inhibitors; hexokinase; tricarboxylic acid cycle; respiratory chain; electron transport chain

Abstract

V originále

The search for mitochondria-targeted drugs has dramatically risen over the last decade. Mitochondria are essential organelles serving not only as a powerhouse of the cell but also as a key player in cell proliferation and cell death. Their central role in the energetic metabolism, calcium homeostasis and apoptosis makes them an intriguing field of interest for cancer pharmacology. In cancer cells, many mitochondrial signaling and metabolic pathways are altered. These changes contribute to cancer development and progression. Due to changes in mitochondrial metabolism and changes in membrane potential, cancer cells are more susceptible to mitochondria-targeted therapy. The loss of functional mitochondria leads to the arrest of cancer progression and/or a cancer cell death. Identification of mitochondrial changes specific for tumor growth and progression, rational development of new mitochondria-targeted drugs and research on delivery agents led to the advance of this promising area. This review will highlight the current findings in mitochondrial biology, which are important for cancer initiation, progression and resistance, and discuss approaches of cancer pharmacology with a special focus on the anti-cancer drugs referred to as ‘mitocans’.

Links

GA18-03978S, research and development project

Name: Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku

Investor: Czech Science Foundation

LM2018133, research and development project

Name: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)

Investor: Ministry of Education, Youth and Sports of the CR

MUNI/A/1307/2019, interní kód MU

Name: Kardiovaskulární systém od A do Z (Acronym: KAVASAZ)

Investor: Masaryk University, Category A

MUNI/A/1453/2019, interní kód MU

Name: Příspěvek ke studiu molekulární, buněčné, tkáňové a systémové patofyziologie vybraných komplexních nemocí

Investor: Masaryk University, Category A

NV18-08-00229, research and development project

Name: Interakce buněk nádorového mikroprostředí jako nový nástroj predikce účinnosti terapie nádorů hlavy a krku

Investor: Ministry of Health of the CR

Citovat

LEISCHNER FIALOVÁ, Jindřiška, Martina RAUDENSKÁ, Milan JAKUBEK, Zdenek KEJIK, Pavel MARTÁSEK, Petr BABULA, Adam MATKOWSKI, Petr FILIPENSKY and Michal MASAŘÍK. Novel Mitochondria-targeted Drugs for Cancer Therapy. Mini-reviews in medicinal chemistry. SHARJAH: BENTHAM SCIENCE PUBL LTD, 2021, vol. 21, No 7, p. 816-832. ISSN 1389-5575. Available from: https://dx.doi.org/10.2174/1389557520666201118153242.

@article{1732814,
   author = {Leischner Fialová, Jindřiška and Raudenská, Martina and Jakubek, Milan and Kejik, Zdenek and Martásek, Pavel and Babula, Petr and Matkowski, Adam and Filipensky, Petr and Masařík, Michal},
   article_location = {SHARJAH},
   article_number = {7},
   doi = {http://dx.doi.org/10.2174/1389557520666201118153242},
   keywords = {Mitochondria; targeting; metabolism; cancer; treatment; inhibitors; hexokinase; tricarboxylic acid cycle; respiratory chain; electron transport chain},
   language = {eng},
   issn = {1389-5575},
   journal = {Mini-reviews in medicinal chemistry},
   title = {Novel Mitochondria-targeted Drugs for Cancer Therapy},
   url = {https://www.eurekaselect.com/188152/article},
   volume = {21},
   year = {2021}
}

TY  - JOUR
ID  - 1732814
AU  - Leischner Fialová, Jindřiška - Raudenská, Martina - Jakubek, Milan - Kejik, Zdenek - Martásek, Pavel - Babula, Petr - Matkowski, Adam - Filipensky, Petr - Masařík, Michal
PY  - 2021
TI  - Novel Mitochondria-targeted Drugs for Cancer Therapy
JF  - Mini-reviews in medicinal chemistry
VL  - 21
IS  - 7
SP  - 816-832
EP  - 816-832
PB  - BENTHAM SCIENCE PUBL LTD
SN  - 13895575
KW  - Mitochondria
KW  - targeting
KW  - metabolism
KW  - cancer
KW  - treatment
KW  - inhibitors
KW  - hexokinase
KW  - tricarboxylic acid cycle
KW  - respiratory chain
KW  - electron transport chain
UR  - https://www.eurekaselect.com/188152/article
N2  - The search for mitochondria-targeted drugs has dramatically risen over the last decade. Mitochondria are essential organelles serving not only as a powerhouse of the cell but also as a key player in cell proliferation and cell death. Their central role in the energetic metabolism, calcium homeostasis and apoptosis makes them an intriguing field of interest for cancer pharmacology. In cancer cells, many mitochondrial signaling and metabolic pathways are altered. These changes contribute to cancer development and progression. Due to changes in mitochondrial metabolism and changes in membrane potential, cancer cells are more susceptible to mitochondria-targeted therapy. The loss of functional mitochondria leads to the arrest of cancer progression and/or a cancer cell death. Identification of mitochondrial changes specific for tumor growth and progression, rational development of new mitochondria-targeted drugs and research on delivery agents led to the advance of this promising area. This review will highlight the current findings in mitochondrial biology, which are important for cancer initiation, progression and resistance, and discuss approaches of cancer pharmacology with a special focus on the anti-cancer drugs referred to as ‘mitocans’.
ER  -

LEISCHNER FIALOVÁ, Jindřiška, Martina RAUDENSKÁ, Milan JAKUBEK, Zdenek KEJIK, Pavel MARTÁSEK, Petr BABULA, Adam MATKOWSKI, Petr FILIPENSKY and Michal MASAŘÍK. Novel Mitochondria-targeted Drugs for Cancer Therapy. \textit{Mini-reviews in medicinal chemistry}. SHARJAH: BENTHAM SCIENCE PUBL LTD, 2021, vol.~21, No~7, p.~816-832. ISSN~1389-5575. Available from: https://dx.doi.org/10.2174/1389557520666201118153242.

Detailed Information on Publication Record